Brief: Deciphera Pharmaceuticals Presents Initial Phase 1 Single Agent Dose Escalation Data For First-In-Class ULK Inhibitor Of Autophagy DCC-3116

Deciphera Pharmaceuticals

10/09/2022 14:40

Sept 10 (Reuters) - Deciphera Pharmaceuticals Inc  DCPH.O :
    * DECIPHERA PHARMACEUTICALS, INC. PRESENTS INITIAL PHASE 1
SINGLE
AGENT DOSE ESCALATION DATA FOR FIRST-IN-CLASS ULK INHIBITOR OF
AUTOPHAGY, DCC-3116, AT THE EUROPEAN SOCIETY FOR MEDICAL
ONCOLOGY (ESMO) CONGRESS 2022
    * DECIPHERA PHARMACEUTICALS INC - DCC-3116 WAS
WELL-TOLERATED WITH
NO DOSE LIMITING TOXICITIES OR TREATMENT-RELATED SERIOUS ADVERSE
EVENTS OBSERVED -
    * DECIPHERA - SELECTION OF STARTING DOSE AND INITIATION OF
COMBINATION DOSE ESCALATION COHORTS WITH MEK AND KRAS(G12C)
INHIBITORS EXPECTED IN Q4 2022

Source text for Eikon:  ID:nBwc3bpgva 
Further company coverage:  DCPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))